The combined therapy with EGFR, BRAF, and MEK inhibition has shown efficacy in BRAF-mutated colorectal cancer, demonstrating the clinical value of using ERBB inhibition to enhance targeting of an MAPK oncogene (32). This evidence concerns the gene EGFR and colorectal cancer.